Vantage logo

The dream is over for Intercept

The company blasts the US regulator as weeks of uncertainty for its lead drug in Nash end in a complete response letter.

Vantage logo

No buyout for Uniqure

But a licensing deal with CSL could have underappreciated benefits, even if expectations were for something much bigger.

Vantage logo

Myovant socks it to Orilissa

Two years after Abbvie’s disappointing launch of Orilissa Myovant hails the development of something much better.